Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions develops and supplies cell processing tools and bioproduction products for the cell and gene therapy market and broader biopharma customers. Company news commonly covers financial results from continuing operations, demand for biopreservation media, and the role of its products in maintaining biologic material during collection, development, manufacturing, storage, distribution, and thawing.
Recurring updates also include product-portfolio expansion, supply agreements for cell and gene therapy manufacturing inputs, CellSeal vial systems, human platelet lysate products, cytokine and growth factor distribution, and research activity tied to biopreservation and cryopreservation technologies.
BioLife Solutions (NASDAQ: BLFS), a leading supplier of bioproduction tools and services for cell and gene therapies and biopharma markets, has announced its second quarter 2024 financial results release date. The company will disclose its Q2 2024 results after market close on Thursday, August 8, 2024. Following the release, BioLife Solutions will host a conference call and live webcast at 4:30pm ET (1:30pm PT) on the same day.
During the call, management will provide an overview of the company's financial performance and offer a general business update. Investors and interested parties can access the webcast through the Investor Relations page on BioLife Solutions' website. For those preferring audio-only participation, a toll-free dial-in option is available. A replay of the webcast will be accessible approximately two hours after the call and will remain archived on the company's investor website for 90 days.
BioLife Solutions (NASDAQ: BLFS) introduced the CryoCase, a new addition to its CellSeal product line at the ISCT Conference in Vancouver. The CryoCase is designed for cell and gene therapy (CGT) primary packaging, aiming to replace cryopreservation bags with a fracture-resistant, rigid construction. It supports both manual and automated, closed-system use.
Available for demonstration at the ISCT event and expected to release to CGT developers in August, the CryoCase offers volume versatility, structural rigidity, and fill/retrieval port designs. It complies with USP 790 and USP 1790 standards and has shown high resistance to leaks and fractures during drop tests.
Early user tests indicated CryoCase may reduce particulates in single-use disposable manufacturing, potentially improving cell viability and recovery. Compatible with BioLife's Signata CT-5 system, CryoCase is expected to lower risks and costs in CGT manufacturing.
BioLife Solutions, Inc. (Nasdaq: BLFS) reported first quarter 2024 financial results with cell processing revenue up 10%, GAAP gross margin at 38%, net loss of $10.2 million, and adjusted EBITDA of $3.6 million. They affirmed revenue guidance for 2024, emphasizing realignment and divestiture of non-core assets to improve financials. Key financial metrics show revenue of $31.7 million, gross margin of 38%, and a net loss of $10.2 million. The company anticipates revenue growth in cell processing and biostorage services platforms.
BioLife Solutions, Inc. (NASDAQ: BLFS) will report its first quarter 2024 financial results on May 9, 2024. The company, a leading supplier of bioproduction tools and services for cell and gene therapies, will host a conference call and webcast to discuss the results and provide a business update. Investors can access the webcast and call details on the BioLife Solutions website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.